Polyol pathway-generated fructose is indispensable for growth and survival of non-small cell lung cancer

• Published in: Cell death and differentiation 2024-11
• Main Authors: Schwab, Annemarie, Siddiqui, Mohammad Aarif, Ramesh, Vignesh, Gollavilli, Paradesi Naidu, Turtos, Adriana Martinez, Møller, Sarah Søgaard, Pinna, Luisa, Havelund, Jesper F, Rømer, Anne Mette A, Ersan, Pelin Gülizar, Parma, Beatrice, Marschall, Sabine, Dettmer, Katja, Alhusayan, Mohammed, Bertoglio, Pietro, Querzoli, Giulia, Mielenz, Dirk, Sahin, Ozgur, Færgeman, Nils J, Asangani, Irfan A, Ceppi, Paolo
• Format: Article
• Language: English
• ISSN: 1350-9047; 1476-5403; 1476-5403
• DOI: 10.1038/s41418-024-01415-1

Despite recent treatment advances, non-small cell lung cancer (NSCLC) remains one of the leading causes of cancer-related deaths worldwide, and therefore it necessitates the exploration of new therapy options. One commonly shared feature of malignant cells is their ability to hijack metabolic pathways to confer survival or proliferation. In this study, we highlight the importance of the polyol pathway (PP) in NSCLC metabolism. This pathway is solely responsible for metabolizing glucose to fructose based on the enzymatic activity of aldose reductase (AKR1B1) and sorbitol dehydrogenase (SORD). Via genetic and pharmacological manipulations, we reveal that PP activity is indispensable for NSCLC growth and survival in vitro and in murine xenograft models. Mechanistically, PP deficiency provokes multifactorial deficits, ranging from energetic breakdown and DNA damage, that ultimately trigger the induction of apoptosis. At the molecular level, this process is driven by pro-apoptotic JNK signaling and concomitant upregulation of the transcription factors c-Jun and ATF3. Moreover, we show that fructose, the PP end-product, as well as other non-glycolytic hexoses confer survival to cancer cells and resistance against chemotherapy via sustained NF-κB activity as well as an oxidative switch in metabolism. Given the detrimental consequence of PP gene targeting on growth and survival, we propose PP pathway interference as a viable therapeutic approach against NSCLC.